Clinical trial · Interventional
Sunitinib in Metastatic Renal Cancer
Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology
NCT01034878CI-TRIAL-00016442completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sunitinib is the registered treatment for first-line therapy of metastatic clear-cell carcinoma of the kidney.Data from the Expanded Access Study have shown activity also in non-clear cell renal cancer (NCCRC). The aim of this study is to prospectively evaluate the anti-tumor activity and safety of sunitinib as a first-line therapy in metastatic NCCRC patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Renal Cell | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sunitinib | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sunitinib
- description
- 50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
- interventionNames
- Drug: Sunitinib
Primary outcomes (1)
- measure
- The antitumor activity in terms of progression free survival
- timeFrame
- two years
Secondary outcomes (3)
- measure
- To evaluate the objective response rate
- timeFrame
- two years
- measure
- To evaluate the toxicity and the safety profile
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven diagnosis of metastatic renal cancer with non-clear cell * No previous treatment Exclusion Criteria: * Prior treatment with an antiangiogenetic compound * Symptomatic and/or unstable pre-existing brain metastases * Severe or uncontrolled cardiovascular diseases
References
Publications (0)
Data not yet available
No reference posted for this study.